Table 2.
Univariable analysis and multivariable analysis of clinical data.
| Variables | Univariable analysis | Multivariate analysis |
|---|---|---|
| ORa (95% CIb) | OR (95% CI) | |
| Age | ||
| ≤60 | Reference | |
| >60 | 1.05 (0.35–3.12) | |
| BMIc | ||
| ≤24 | Reference | |
| >24 | 1.22 (0.35–4.58) | |
| Tumor location | ||
| Upper thorax | Reference | |
| Middle thorax | 1.33 (0.31–5.85) | |
| Lower thorax | 1.71 (0.36–8.4) | |
| cT stage | ||
| cT1–cT2 | Reference | |
| cT3–cT4 | 0.89 (0.26–2.93) | |
| cN stage | ||
| cN0 | Reference | Reference |
| cN1–cN3 | 10 (2.64–49.97) | 10.82 (0.93–296.01) |
| Stage | ||
| I–II | Reference | Reference |
| III–IV | 4.5 (1.41–15.74) | 0.43 (0.02–4.18) |
| Pathological differentiation | ||
| Moderately | Reference | |
| Poorly | 2.17 (0.64–7.71) | |
| Unknown | 5.78 (1.37–31.12) | |
| Treatment cycles | ||
| 2 cycles | Reference | |
| >2 cycles | 0.97 (0.19–5.33) | |
| Radiotherapy | ||
| Yes | Reference | Reference |
| No | 11.14 (3.40–41.98) | 7.77 (2.11–31.98) |
| Interval time* | ||
| ≤90 days | Reference | |
| >90 days | 0.37 (0.11–1.22) | |
*Means the time from the day of first neoadjuvant immunotherapy to the day of surgery. aOdds ratio. bConfidence interval. cBody mass index.
Bold numbers mean a p-value less than 0.05.